Commentary

Video

Recapping the Latest in AML With Dr Eunice Wang

Author(s):

Eunice Wang, MD,Chandler Park, MD, MSc, FACP

Eunice Wang, MD, of Roswell Park Comprehensive Cancer Center, sits down with Chandler Park, MD, FACP, to discuss the latest in acute myeloid leukemia from the 2024 ASH Annual Meeting.

Eunice Wang, MD, of Roswell Park Comprehensive Cancer Center, sits down with Chandler Park, MD, FACP, to discuss the latest in acute myeloid leukemia from the 2024 ASH Annual Meeting.

Related Videos
Nosha Farhadfar, MD, and Chandler Park, MD, FACP
Prithviraj Bose, MD, and Chandler Park, MD, FACP
Muhamed Baljevic, MD, FACP and Jorge Cortes, MD, discuss upcoming studies and emerging data being presented at the 2024 ASH Annual Meeting.
Minoo Battiwalla, MD, MS
Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.
Francine Foss, MD
David C. Fisher, MD
Michel Delforge, MD, PhD, professor, Faculty of Medicine, Department of Hematology, director, member, Leuven Cancer Institute, member, Senior Academic Staff, Council of the Faculty of Medicine, Council of the Department of Oncology, University Hospital Leuven, University of Leuven
Farrukh Awan, MD
Minoo Battiwalla, MD, MS
Related Content
Multiple myeloma
December 9th 2024

Belantamab Mafodotin Combo Could Be New SOC for Relapsed/Refractory Multiple Myeloma

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

B-Cell Malignancies
December 9th 2024

Second-Generation BTK Inhibitors Exhibit Lower Incidence of Cardiac AEs in B-Cell Malignancies

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

MCL and ALL - stock.adobe.com.
December 9th 2024

Outpatient Lymphodepletion Before Brexu-Cel Remains Safe, Efficacious in Mantle Cell Lymphoma and Acute Lymphoblastic Leukemia

DLBCL | Image credit: ©Nittaya– stock.adobe.com
December 9th 2024

Zilovertamab Vedotin Plus R-CHP Yields 97.2% Overall CR Rate in DLBCL